^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Clear Cell Renal Cell Carcinoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ASCO.org
    Title:

    Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline

    Published date:
    06/21/2022
    Excerpt:
    Nivolumab or cabozantinib should be offered to patients who progressed on a VEGFR TKI alone…
    DOI:
    10.1200/JCO.22.00868
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma

    Published date:
    12/01/2021
    Excerpt:
    For second-line treatment, following TKIs, nivolumab [l, A; ESMO-MCBS v1.1 score: 5] or cabozantinib is recommended [l, A; ESMO-MCBS v1.1 score: 3]….In patients already treated with two lines of TKI therapy and whose disease has progressed, either nivolumab [I, A; ESMO-MCBS v1.1 score: 5] or cabozantinib [I, A; ESMO-MCBS v1.1 score: 3] may be considered.
    DOI:
    https://doi.org/10.1016/j.esmoop.2021.100304